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Abstract 
The economic evaluation of medical devices is increasingly used to inform decision making on adopting new or 
novel technologies; however, challenges are inevitable due to the unique characteristics of devices. Cost-
consequence analyses are recommended and employed by the English National Institute for Health and Care 
Excellence (NICE) Medical Technologies Evaluation Programme (MTEP) to help address these challenges. The 
aim of this work was to review the critiques raised for previous MTEP submissions and explore if there were 
common problems across submissions. We reviewed a sample of 12 economic submissions to MTEP 
representing 50 % of 24 sets of guidance issued to July 2015. For each submission, we reviewed the External 
$VVHVVPHQW &HQWUH¶V ($& UHSRUW DQG WKH JXLGDQFH GRFXPHQW SURGXFHd by NICE. We identified the main 
problems raised by WKH ($&¶V DVVHVVPHQWV DQG the FRPPLWWHH¶V FRQVLGHUDWLRQV IRU HDFK VXEPLVVLRQ DQG
explored strategies for improvement. We found that the identification and measurement of costs and 
consequences are the main shortcomings within economic submissions to MTEP. Together, these shortcomings 
accounted for 42 % of criticisms by the EACs among the reviewed submissions.  In certain circumstances 
problems with these shortcomings may be unavoidable, for example, if there is a limited evidence base for the 
device being appraised. Nevertheless, strategies can often be adopted to improve submissions, including the use 
of more appropriate time horizons, whilst cost and resource use information should be taken, where possible, 
from nationally representative sources.   
     
Key points for decision makers 
x The identification of costs and consequences, together with their measurement are the main shortcomings 
within economic submissions to MTEP.  
x The main strategies to reduce these include using national references for unit costs and ensuring that the 
time horizon for the analysis is long enough to capture all relevant costs and health effects.     
x Shortcomings with evidence identification and interpretation of the decision problem are also prevalent. 
Sponsors should be encouraged to use well-structured search strategies and follow the scope specified by 
NICE. Presentation and interpretation of results were identified less often to be a problem within MTEP 
submissions.    
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1. Introduction  
The economic evaluation of medical devices is increasingly used to inform decision making on adopting new or 
novel technologies; however, challenges are inevitable due to the unique characteristics of devices [1-3]. The 
economic impact of medical technologies constitutes a substantial proportion of health spending, with an 
estimated 7.5 % of the total European health expenditure and 4.5 %  in the UK [1]. In 2009, the English 
National Institute for Health and Care Excellence (NICE) introduced the Medical Technologies Evaluation 
Programme (MTEP) to evaluate devices whilst recognising the unique challenges this presents [1, 4].    
The methods adopted by NICE for health technology assessments (HTAs) differ depending on the type of 
technology being appraised. In particular, the decision-making context differs when comparing medical devices 
to pharmaceuticals and this reflects the complexities of evaluating technologies with distinct properties.  For 
instance, the NICE technology appraisal programme adopts cost-utility analysis as a primary method of 
economic evaluation of pharmaceuticals, which produces values in terms of incremental cost per quality-
adjusted life years (QALYs) gained. However, cost-consequence analysis has been recommended and adopted 
as an appropriate method for evaluating medical devices within MTEP [5, 4]. During cost-consequence analysis 
the costs and benefits of a technology are compared to suitable alternatives, with benefits kept as a natural unit 
and not defined as a single measure, such as QALYs for cost-utility analysis [6].  
1.1 Why are Medical Devices Different?  
Medical devices are different from pharmaceuticals in many aspects [1, 3]. A key difference is that product life 
span for medical devices are generally shorter. This has implications on research and development spending, 
which, in turn, has a negative effect on evidence production [1]. Evidence production can also be limited with 
medical devices because designing an appropriate trial to evaluate the efficacy of the technology can be 
challenging. These challenges occur because medical devices often have multiple applications and the outcomes 
with a particular device may largely be driven by the skill of the operator. Furthermore, blinding of investigators 
and patients can often be difficult, or altogether impossible, which increases the risk of bias [7]. The impact of 
these characteristics is exacerbated by the fact that devices manufacturers are overwhelmingly small or medium-
sized enterprises (SMEs), with limited research and development budgets [1]. Issues relating to unpublished 
studies and reporting bias for medical devices were highlighted by a guideline recently published by the 
European network for HTA (EUnetHTA) [8]. Therefore, evaluating medical devices in a different way to 
pharmaceuticals is required in order to take these characteristics into account.  
1.2 Economic Submissions to NICE Medical Technologies Evaluation Programme  
The MTEP process involves three key activities: (i) identification and selection of technologies that would 
benefit from national evaluations; (ii) routing of technologies by the medical technologies advisory committee 
(MTAC) for evaluation within the programme at NICE deemed most relevant; (iii) appraisal of technologies [9]. 
Prior to this appraisal process MTEP musW EH PDGH DZDUH RI D WHFKQRORJ\¶s suitability for assessment and 
primarily the manufacturer of the medical device (sponsor) will notify NICE. Medical devices that are likely to 
be cost saving or cost neutral will generally be routed to MTEP, whilst technologies with more complex value 
propositions, such as those that generate additional health benefits (e.g. QALYs) but at a greater cost, may be 
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routed to alternative NICE programmes. These include the Technology Appraisal Programme and the 
Diagnostic Appraisal Programme [5]. Those devices that are routed through MTEP are evaluated based on the 
sponsor¶V FOLQLFDO DQG HFRQRPLF HYLGHQFH VXEPLVVLRQ The economic submission by the sponsor of a new 
medical device is a key element required by MTEP to assess the value of the technology to the National Health 
Service (NHS).  The submitted evidence is critically assessed by an External Assessment Centre (EAC), an 
independent group commissioned by NICE, and their assessment report is considered by the committee, 
together with other information, to make recommendations. As part of their work the EAC may also undertake 
additional economic modelling, which should further inform the recommendations made by the committee. 
Recommendations on individual medical devices within MTEP are generally made on the basis of its potential 
for producing cost savings to the NHS and other patient benefits. MTEP can provide a number of different 
recommendations on individual devices, including: full recommendation, recommendation for specific 
circumstances, recommended in research and not recommended [5]. For all technologies that are evaluated via 
MTEP, the process will be summarised via medical technical guidance (MTG) and its publication is the final 
step in the evaluation.     
1.3 Why We Might Expect Problems Within Economic Evaluations of Medical Devices?   
Although the MTEP methods and process guides were developed to take into account the unique challenges that 
exist when undertaking an economic assessment of medical devices, we might still expect problems with 
economic analyses in practice. A less onerous regulatory framework, together with the limitations of being 
relatively small companies, has discouraged investment in economic expertise within SMEs [1]. At the time this 
review was started (July 2015) MTEP had published 24 sets of guidance on individual medical technologies 
since its introduction. This provides a good source of evidence for assessing the application of economic 
analyses within MTEP.  
1.4 Objectives of this Review 
The aim of this review was to summarise the critiques of VSRQVRU¶V submissions to MTEP. The specific 
objectives were to identify any problems with the application of methods, explore which particular problems 
were more common as raised by the EAC¶s and the committee¶s discussions, and identify strategies for 
improvement in submission quality. Therefore, this review focuses on the appraisal of technologies by MTEP 
and does not consider the process for the identification, selection and routing of technologies. We reviewed the 
($&¶VFULWLTXHDQGFRPPLWWHHFRQVLGHUDWLRQVRI economic submissions to NICE MTEP.  
2. Methods 
We reviewed a sample of 12 economic submissions to MTEP representing 50 % of the 24 sets of full guidance 
issued up to the time the sample was selected for this review. We used proportionate stratified random sampling 
to ensure that each category of medical devices and committee recommendations were represented in the 
sampling process. First, we split the sampling frame of the 24 sets of technologies into different strata to ensure 
a mix of devices, diagnostics and systems, together with mix of committee recommendations. Then we used 
random sampling techniques and selected a proportionate sample of 12 technologies included in this review. 
Only 12 submissions were selected for assessment due to time and budgetary constraints; however, given the 
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sampling technique we followed, we deem that these are reasonably representative of all economic submission 
to MTEP.  
For each submission, two key documents were reviewed; the EAC¶V DVVHVVPHQW report and the guidance 
document produced by NICE. Each document was reviewed by a single reviewer (AA, WG or MJ) and checked 
by a second reviewer (SD, WG or MJ). To avoid bias, those sets of guidance for which the authors or their 
institutions had been involved in developing were reviewed by an independent person. We followed the six 
stages specified by Drummond et al within their checklist for assessing economic evaluations in health care 
[10]. These are: decision problem interpretation and evidence identification; cost and consequence 
identification; measurement and valuation; choice of model and analysis; and presentation and interpretation of 
results. 
First, the assessment report produced by the EAC was reviewed according to 13 criteria, of which 12 items were 
taken from a list of 24 checklist items included within the CHEERS checklist [11], and 1 item (searching for 
economic studies) is driven by the six stages  of economic evaluation [10] and the MTEP methods guide [5].  
Searching for published evidence is a substantial component of submissions to MTEP; and therefore, it is 
reasonable to be included as part of our assessment criteria. Only those checklist items relevant to MTEP 
economic submissions were included. These comprised: searching for economic studies, target population and 
subgroups, setting and locations, perspective, comparator, choice of health outcomes, estimating resources and 
costs, choice of model, time horizon, measurement of effectiveness, parameters, characterising uncertainty and 
presentation and interpretation of results (used instead of reporting incremental costs and outcomes) . Although 
the µsearching for published evidence¶ item overlaps with µestimating resources and costs¶ in the CHEERS list, 
we decided to keep this item separate as it is an integral part of economic submissions to MTEP.  The checklist 
items excluded (with reason in brackets) are: title, abstract, background and objectives, valuation of preference-
based outcomes, discussion, source funding, conflict of interest (more relevant to publications); discount rate, 
currency/price date, assumptions, analytic methods, characterising heterogeneity (related to model assessment). 
Since we didn¶WUHYLHZthe published evidence used, submissions or the models directly, we decided to exclude 
these 12 items from our assessment criteria.  All EAC critiques were extracted and briefly described under the 
thirteen headings considered.  
Second, the main issues considered and discussed by the committee were summarised under the same thirteen 
headings listed previously. Third, the key problems raised E\ WKH ($&¶V DVVHVVPHQWV DQG FRPPLWWHH¶V
considerations were matched and presented into a tabular format to compare across reviewed submissions. 
Fourth, the key problems identified were then grouped into six categories representing the different stages of 
economic evaluation in health care [10]. The 13 criteria specified above were each placed under one of the six 
categories. Finally, strategies for improvement for each set of problems were then identified based upon the 
MTEP methods guide and critiques provided by both the EACs and committee [5].     
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3. Results  
A sample of 12 submissions was included in this review including 8 (67 %) technologies that had received 
positive recommendations for use in either the whole patient population as specified by the scope or in a 
subgroup of patients. The mix of sampled technologies included seven medical devices (58 %), two diagnostics 
(17 %) and three systems (technologies with system in the name, expected to comprise multiple components) 
(25 %). The list of medical technologies included in this review is presented in Table 1.   
The main problems picked up by the EAC¶V DVVessment and committee¶V considerations for each medical 
technology are presented in the following subsections. A detailed description of the highlighted problems is 
provided as supplementary information.  
3.1 Parafricta Bootees and Undergarments to Reduce Skin Breakdown in People with or at Risk of Pressure 
Ulcers 
Three main critiques were raised by the EAC¶VHFRQRPLF assessment for Parafricta bootees and undergarments. 
These were: a lack of evidence on the effectiveness of the device in the community setting, a number of 
assumptions and estimates used to inform the economic model were incorrect or implausible, and the model 
structure was not appropriate [12]. The committee discussed three key cost-related issues: choice of the model, 
model parameters and uncertainty of results [13]. It concluded that further research is necessary to assess the 
length of stay in hospital, severity of pressure ulcers and the cost associated with pressure ulcers. The 
FRPPLWWHH¶VILQDOGHFLVLRQ on this device recommended further research to address uncertainties relating to the 
claimed patient and system benefits.    
3.2 The Geko Device for Reducing the Risk of Venous Thromboembolism 
TKH($&¶VDVVessment report included a minor criticism of the unit costs utilised within the economic model 
and a more serious criticism around the clinical assumption underpinning the model [14]. 7KH FRPPLWWHH¶V
discussions were focused around the plausibility of the assumption made by the sponsor relating to the clinical 
effectiveness of the device [15]. They recommended the geko device for people who have high risk of venous 
thromboembolism and for whom other mechanical and pharmacological methods of prophylaxis are impractical 
or contraindicated.  
3.3 The MAGEC System for Spinal Lengthening in Children with Scoliosis 
7KH($&UDLVHGVL[LVVXHVDVVRFLDWHGZLWKWKHVSRQVRU¶VHFRQRPLFVXEPLVVLRQ The main problems were a poor 
search strategy for evidence, an inappropriate costing approach and the use of a model structure that had not 
been validated [16].  The EAC carried out additional work, which included: the DGDSWDWLRQ RI WKH VSRQVRU¶V
model (making it fully executable), updating some inputs to the model with more appropriate estimates and 
conducting sensitivity analyses to address uncertainty. The committee¶V discussion was focused around the use 
of the device among a subgroup of children with less than 35 months growth potential, the time horizon of the 
analysis and the additional cost savings which could be generated from not using spinal cord monitoring with 
the MAGEC system [17]. This technology was recommended for use in children with scoliosis aged 2 years and 
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over who require surgery to correct their spinal curvature when conservative methods such as bracing or casting 
have failed.       
3.4 The E-Vita Open Plus for Treating Complex Aneurysms And Dissections of The Thoracic Aorta 
The EAC highlighted five issues within the economic section of their assessment pertaining to the literature 
search, the economic model structure and time horizon as well as the presentation of the results of the analysis 
[18] 7KH FRPPLWWHH¶V GLVFXVVLRQ ZDV focused around the time horizon of the analysis and impact of the 
potential need for re-intervention on the effectiveness of the device [19]. The committee recommended adopting 
E-vita open plus to treat complex aneurysms and dissect the thoracic aorta in the patients who would otherwise 
need a two-stage repair procedure, but would not need an additional intervention in the descending aorta.  This 
population was a subgroup of the original population evaluated as defined by the scope issued by NICE.   
3.5 Ambu Ascope2 for Use in Unexpected Difficult Airways 
Six issues were described by the EAC within the economic section of their assessment report relating to the 
literature search and the economic moGHO¶VVWUXFWXUHDQG LQSXWs [20]. The committee had a number of serious 
considerations relating to the clinical setting modelled and the evaluation of uncertainty within the model [21].  
Based on these considerations the committee requested additional cost modelling from the EAC in order to aid 
their decision making. The committee¶V ILQDO GHFLVLRQ recommended the adoption of Ambu aScope2 as an 
acceptable alternative for emergency intubation in people with unexpected difficult airways where a multiple-
use fibre optic endoscope is unavailable. 
3.6 Watchbp Home A for Opportunistically Detecting Atrial Fibrillation During Diagnosis and Monitoring 
of Hypertension 
7KH($&¶V assessment identified a number of issues with the economic evidence submission. These included  
the estimation of costs from a societal perspective , the use of an inappropriate approach for estimating the target 
population expected to benefit from the device and use of a population in the economic analyses which differed 
from that specified in the scope [22]. The EAC undertook additional economic modelling work to resolve some 
of these issues. The main points discussed by the committee included the unknown cost impact of using this 
technology on younger populations due to lack of evidence and the uncertainty associated with the cost of stroke 
[23] 7KHFRPPLWWHH¶V ILQDO GHFLVLRQ UHFRPPHQGHG WKHXVHRI:DWFK%3+RPH$ device for people who are 
having their blood pressure checked in primary care (for example, at a GP surgery or clinic). 
3.7 The Veriq System for Assessing Graft Flow During Coronary Artery Bypass Graft Surgery 
Within the economic section of the ($&¶V DVVHVVPHQW UHSRUW ILYH problems were identified relating to the 
VSRQVRU¶V VHDUFK VWUDWHJ\ WKHLU economic model structure and the limited analyses of uncertainty within the 
model [24]. The FRPPLWWHH¶Vdiscussions were focused around the estimation of resource use and costs as well 
as the choice of other parameters within the analysis [25]. The committee recommended the adoption of the 
VeriQ system for assessing graft flow during coronary artery bypass graft (CABG) surgery.  
3.8 Inditherm Patient Warming Mattress for The Prevention of Inadvertent Hypothermia 
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7KH($&¶VDVVHVVPHQWUHSRUW UDLVHGVL[ issues relating to the economic submission of this technology. These 
included limitations in the literature searching strategy, not undertaking subgroup analysis specified by the 
scope, the estimation of costs, the economic model structure, plausibility of parameters used, and that sensitivity 
analyses were poorly conducted [26]. The committee¶V discussion focused on two points: the cost associated 
with purchasing additional Inditherm components and the credibility of estimated cost savings [27]. The 
committHH¶V ILQDO GHFLVLRQ UHFRPPHQGHG WKH XVH RI the Inditherm Patient Warming System for patients 
undergoing operations that carry a risk of inadvertent hypothermia. 
3.9 Ambulight PDT for the Treatment of Non-Melanoma Skin Cancer 
Three main issues were identified by the EAC in the economic section of their assessment report which related 
to the estimation of resource use, the literature searches and lack of sensitivity analyses to explore uncertainty 
within the economic model [28].  The committee discussed issues relating to the health-care setting that was 
modelled as well as the poor presentation of the PRGHO¶Vresults [29].  The committee reported that the case for 
adopting Ambulight PDT was not supported by the evidence.  This was due to a limited amount of clinical 
evidence and high levels of uncertainty relating to the cost implications of the device.    
3.10 The MIST Therapy System for the Promotion of Wound Healing 
The EAC critiqued the economic evidence submission and raised four main issues. These were the estimation of 
resources and costs, the choice of health outcomes, measurement of effectiveness and the limited time horizon 
of the model [30]. Three main issues were considered by the committee: estimating resource use and costs, 
measurement of effectiveness, and characterising uncertainty [31] 7KH FRPPLWWHH¶V ILQDO GHFLVLRQ
recommended further research to address the uncertainty associated with the relative clinical effectiveness of the 
MIST Therapy system.    
3.11 BRAHMS Copeptin Assay to Rule Out Myocardial Infarction in Patients with Acute Chest Pain 
The EAC identified a large number of issues associated with the economic evidence submission with the key 
issues being the estimation of resources and costs, the time horizon of the model and the measurement of 
effectiveness [32].  The main issues discussed by the committee were the sources and estimation of resource use 
and costs utilised within the economic model [33].  The committee recommended further research within a UK 
clinical setting to compare the BRAHMS copeptin assay in combination with cardiac troponin testing against 
sequential cardiac troponin testing for ruling out myocardial infarction. 
3.12 Sequent Please Balloon Catheter for In-Stent Coronary Restenosis 
The main issues raised by the EAC following critique of the economic evidence submission were that not all 
patient subgroups were included as specified by the scope, the evidence was taken from a German setting, the 
economic model structure had not been validated, and there was a lack of probabilistic sensitivity analyses [34]. 
7KH FRPPLWWHH¶V discussion was focused around four issues: the comparator treatment within the model, the 
time horizon of the analysis, model input parameters and uncertainty in results [35]. The committee 
recommended the use of SeQuent Please balloon catheter for use in patients with in-stent restenosis in bare 
metal coronary artery stents. 
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Summarising MTEP Economic Submission Critiques 
The types of problems raised by either the EAC or the committee varied between submissions with some 
common issues, as shown in Table 2. The proportions of submissions with problems in each category based on 
the EAC assessments are shown in Table 2. The most prevalent shortcomings according to the EAC assessments 
were cost and consequence identification and measurement, as well as decision problem definition and evidence 
identification (Fig. 1).  Twenty-one percent of the issues identified fell into each of these categories.  Other 
issues, including problems with the presentation and interpretation of results, were far less frequent (6 %).  
Figure 1 presents the proportions of problems within economic submissions to MTEP as identified by the EAC 
for all categories based on the different stages of economic evaluation in health care.     
4. Discussion   
Through an analysis of a sample of previous submissions to MTEP, cost and consequence identification and 
measurement were found to be the most prevalent shortcomings within economic submissions to MTEP. These 
consist of estimating resource use and costs, choice of health outcomes and choice of parameter estimates used 
to inform the economic model. To avoid these problems, cost and resource use information should be taken 
from national estimates or nationally representative sources where possible.  Data from national databases 
should be supplemented with systematic searches of the published literature, where required.  Where less 
applicable evidence is available or assumptions need to be made, validation by clinical experts should be sought. 
Another prevalent shortcoming is the evidence identification and interpretation of the decision problem by the 
sponsor, which includes searching for economic studies, target population and subgroups, setting and location, 
perspective and comparator(s). Similar to our findings, the EUnetHTA guide has identified obtaining full 
information about the existing evidence and publication bias as issues requiring specific attention since data on 
high-risk medical devices remain unpublished [8]. The guidance suggested broadening literature searches to 
include the best available evidence since the approval process of medical devices within Europe does not require 
randomised controlled trial evidence on efficacy and effectiveness. However, SMEs have previously noted that 
undertaking literature searches and obtaining relevant academic papers is a timely and expense process that 
prohibits the completion of submissions [36]. Furthermore, in many cases it is not be possible to identify 
relevant evidence to use in the submission, as medical devices are often associated with limited evidence bases 
for the reasons discussed in Sect. 1.1. Nevertheless, submissions could still be improved if manufacturers are 
able to undertake more structured search strategies of the databases recommended by MTEP and by matching 
the economic model to the decision problem specified by NICE within their scope.  
Other shortcomings identified by our review related to the time horizon of the model, choice of the model 
structure and presentation of results. The time horizon for cost and consequences valuation should be long 
enough to capture any cost differences between the device in question and its comparator(s). The choice of the 
model and the analysis conducted led to issues including a lack of exploration of uncertainty and the exclusion 
of relevant device related adverse events within the analysis. Uncertainty within models can be explored through 
the use of sensitivity analysis, whilst all relevant adverse events should be included within the model. The 
incorrect use of perspective was only identified in one submission, that of ³:DWFK %P +RPH $´, where 
modelling was undertaken from societal perspective. This should be undertaken from the NHS and personal 
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social services perspective in line with the MTEP methods guide [5]. Finally, issues around the presentation and 
interpretation of results can be mitigated by highlighting the most realistic scenario and presenting the results 
from other, supplementary, scenarios within the submission.  
More generally, there was little evidence in the vast majority of the submissions of a clear conceptual basis for 
the structure of the model in terms of which events and outcomes were captured, how they should be measured 
and over what time frames.  µConceptual modelling¶ is an important part of model development and its use can 
help guard against contextually inadequate models [37]. Whilst there is no direct evidence relating to the extent 
of any conceptual modelling that supported the economic submissions, our overall conclusions are consistent 
with the view that such modelling was generally inadequate. 
A previous review of MTEP suggested that the programme has some way to go to meet its principal aims [1]. 
These aims were: simplifying access to evaluation, speeding up the assessment and appraisal process and 
increasing the evaluative capacity within NICE. Our findings from this review provide an insight into the 
practical application of MTEP methods over the past five years. Limitations of evidence and knowledge about 
economic evaluations within devices companies are evident. Guidance for early assessment of medical devices 
is available in the literature [38-40]; however, they do not appear to be cited or applied within the economic 
submissions to MTEP across the board. This review also highlights deficiencies in the economic models 
submitted by sponsors. In many case these deficiencies are inevitable, particularly given the issues with 
evidence production that have been discussed previously. Furthermore, sponsors may lack the relevant training 
and resources to develop economic models that meet the requirements of MTEP. One potential solution would 
be to request that the EAC assists the sponsor with their economic submission, or perhaps completes the 
submission themselves. Given the EAC already commonly undertakes additional modelling as part of their 
contribution,  this is unlikely to result in extra work and in fact may allow more robust models to be developed 
in an efficient manner. If the EAC were to complete the initial submission the sponsor could provide input at 
designated time points to ensure the EAC is fully informed in regards to the device in question. This proposal 
would have similarities with the process followed by the Diagnostic Assessment Programme at NICE [41].  If 
the burden on the sponsor were to be reduced, this may also encourage more SMEs to notify NICE of their 
technology, increasing the pool of innovative technologies that NICE has the opportunity to appraise. If there is 
a significant increase in notifications, the MTEP routing process may have to be adjusted to ensure the most 
relevant technologies are prioritised for appraisal.  
The two main strengths of this work are, first, that it is the first known critical appraisal of economic 
submissions to MTEP and, second, by looking at the both the EAC and committee documents, those problems 
that were of particular concern to decision makers were identified. However, there are also several limitations. 
First, we did not review each of the submissions directly, but relied on the critiques of the EACs and the 
committee. There are four different EACs that work with NICE for MTEP currently and additional centres have 
been involved previously. Each EAC may apply distinct methodologies for their critique process. Second, it is 
based on small sample size of 12 technologies. Third, no differentiation or weighting was given to the size of 
each problem identified. And finally, WKH FRPPLWWHH¶V ILQDO GHFLVLRQ GRHV QRW only rely on the sponsor¶V
VXEPLVVLRQDQG($&¶VUHSRUWEXWPD\FRQVLGHUother evidence such as consultations from clinical experts and 
patient groupsDVZHOODVWKHVSRQVRU¶VVXEPLVVLRQ, which were not considered here. 
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Overall, this review generates a good, initial, understanding of the application of methods for economic analyses 
employed by the MTEP for evaluating medical devices. The results suggest that there are common problems 
with the economic evidence submitted by medical device companies within one national guidance process. This 
is despite the fact that the required methods are simpler than those seen for pharmaceutical products.  If decision 
makers want device manufacturers to produce better quality evidence, then methods by which this can be 
achieved need to be explored.  Without this, the guidance process will continue to spend resources on amending 
flawed analyses or potentially rejecting technologies due to inadequacies in the submissions. These 
consequences have the effect of limiting the opportunities for manufacturers who are faced with short product 
lifespans. 
5. Conclusions  
Although previous reviews about the role of MTEP have highlighted some challenges, to the best of our 
knowledge, this is the first review of individual submissions to MTEP. Shortcomings within the economic 
submissions were identified based on the EACs assessment and matched with MTAC¶V considerations. These 
shortcomings might have implications for the aims of MTEP, which include speeding-up evaluation and 
encouraging early uptake of novel medical technologies in the NHS. Cost and consequence identification and 
measurement are the main limitations of economic submissions to MTEP; using national reference costs and 
systematic searching of the literature can be followed as strategies to reduce these problems.  
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Table 1 List of medical devices included in this review ʹ this includes a categorisation of the type of device 
and the date on which the final guidance was published 
Medical technologies guidance Category  Final guidance 
publish date 
Parafricta Bootees and Undergarments to reduce skin breakdown in 
people with or at risk of pressure ulcers (MTG20) 
Device November 2014 
The Geko device for reducing the risk of venous thromboembolism 
(MTG19) 
Device June 2014 
The MAGEC system for spinal lengthening in children with scoliosis 
(MTG18) 
System June 2014 
The E-vita open plus for treating complex aneurysms and dissections of 
the thoracic aorta (MTG16) 
Device December 2013 
Ambu aScope2 for use in unexpected difficult airways (MTG14) Device July 2013 
WatchBP Home A for opportunistically detecting atrial fibrillation 
during diagnosis and monitoring of hypertension (MTG13) 
Diagnostic January 2013 
The VeriQ system for assessing graft flow during coronary artery bypass 
graft surgery (MTG8) 
System November 2011 
Inditherm patient warming mattress for the prevention of inadvertent 
hypothermia (MTG7) 
Device  August 2011 
Ambulight PDT for the treatment of non-melanoma skin cancer (MTG6) Device July 2011 
The MIST Therapy system for the promotion of wound healing (MTG5) System July 2011 
BRAHMS copeptin assay to rule out myocardial infarction in patients 
with acute chest pain (MTG4) 
Diagnostic June 2011 
SeQuent Please balloon catheter for in-stent coronary restenosis (MTG1) Device  December 2010  
 
MTG=medical technology guidance, PDT=photodynamic therapy.  
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Table 2 Overview of the problems raised by the EACs and Committee's considerations across submissions. Problems were separated into six groups, and further categorised into thirteen issues. For 
each of the 12 submissions assessed, problems raised within the EAC assessment and those discussed by the committee, are indicated separately. 
 
Category of problem raised 
 
Medical technologies guidance 
Group 
% of 
problems 
raised by 
the EACs  
Issue Parafricta Geko MAGEC System E-vita 
Ambu 
aScope 
WatchB
P Home 
A 
VeriQ Inditherm PWM 
Ambulig
ht 
MIST 
Therapy 
System 
BRAM
HS SeQuent 
Question/ 
decision 
problem 
interpretation 
and evidence 
identification 
21% Searching for 
economic studies 

8 



8

8

8

8+

8

8

8
 
8

8
Target 
population and 
subgroups 
 
 
+
 


8+
 
8
   
8
Setting and 
location 
 
   
8+

8+
  
+
  
8
Perspective      8+
     

Comparator      8+
    
8

8+
Cost and 
consequences 
identification 
21% Estimating 
resources and 
costs 

8 

8

8+
 
8

8+

+

8+

8

8+

8+

8
Choice of health 
outcomes 

8 


  


8+

8
  
8+



Costs and 
consequences 
measurement 
21% Measurement of 
effectiveness 

 

8+
 
+

8




  
8+

8

Parameters  8+ 



8+

8
 
8+

8+

8
 


8

+
Costs and 
consequences 
valuation 
12% 
Time horizon 

8 
 
8

8+
 



  
8+

8

8+
Analysis 19% Choice of model 8+ 
 
8+
 
8

8+

8

8+


 
8

8
Characterising 
uncertainty 

8+ 
 
8
 
+

8+

8

8

8
 
8

8+
Presentation 
and 
interpretation 
of results 
6% Presentation and 
interpretation of 
results 
 
  

8


8
   

+
 

8


 
 
NICE final decision  Further 
research 
Recommend
ed for 
population in 
Scope 
Recommended 
for population 
in Scope 
Recommend
ed for a 
subgroup of 
the 
population in 
Scope 
Recommend
ed for a 
subgroup of 
the 
population in 
Scope 
Recomm
ended 
for 
populati
on in 
Scope 
Recommend
ed for 
population in 
Scope 
Recomme
nded for a 
subgroup 
of the 
population 
in Scope 
Not 
recomme
nded 
Further 
research 
Furthe
r 
researc
h 
Recommended for 
population in 
Scope 
8 Represents a problem with the methods used by the sponsor UDLVHGE\WKH($&¶VDVVHVVPHQW 
+ Represents a discussion by the committee around the methods used by the sponsor 
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Fig. 1 Common problems identified by the EACs assessment across economic submissions ʹ Problems idenified by the 
EAC were separated into six categories.  The percentages reflect the proportion of all porbelmce that fit into each category.  
 
EAC external assessment centre 
